ArticleLancet (London, England)2021
Age and frailty in COVID-19 vaccine development.
Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Influenza vaccine effectiveness according to frailty status in adults aged ≥ 50 years: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials.Clinical interventions in aging · 2022Trial
- Travel vaccination in senior travelers: current evidence, challenges, and prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Physical activity during COVID-19 pandemic: A 5-year retrospect.Sports medicine and health science · 2025Review
- Population-Based Analysis of Vaccination Status and Post-Vaccination Adverse Events in Adults Aged 55 and Older.Journal of clinical medicine · 2025Article
- Neutralizing antibody responses to three XBB protein vaccines in older adults.Signal transduction and targeted therapy · 2025Article
- SARS-CoV-2 vaccination in children and adolescents with and without type 1 diabetes mellitus.Endocrine · 2023Review
- Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults.Immunity & ageing : I & A · 2023Article
- Sialic acid-mediated photochemotherapy enhances infiltration of CD8Acta pharmaceutica Sinica. B · 2023Article
- Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data.The journal of nutrition, health & aging · 2023Article
- Self-Reported Reactogenicity After Different COVID-19 Vaccination Regimens—an Analysis of Registry-Based Data.Deutsches Arzteblatt international · 2022Article
- Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study.The Lancet regional health. Europe · 2022Article
- Age discrimination, the right to life, and COVID-19 vaccination in countries with limited resources.The Journal of social issues · 2022Article
- COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.The lancet. Healthy longevity · 2022Article
- Frailty and Age Impact Immune Responses to Moderna COVID-19 mRNA Vaccine.Research square · 2022Article
- COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.Clinics in geriatric medicine · 2022Review
- Frailty and COVID-19 mRNA Vaccine Antibody Response in the COVID-19 Community Research Partnership.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Observational
- Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents.Drugs & aging · 2022Observational
- Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population.Age and ageing · 2022Article
- The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models.Pharmaceutics · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.